549 related articles for article (PubMed ID: 15217493)
1. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
[TBL] [Abstract][Full Text] [Related]
2. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
Machiels JP; Reilly RT; Emens LA; Ercolini AM; Lei RY; Weintraub D; Okoye FI; Jaffee EM
Cancer Res; 2001 May; 61(9):3689-97. PubMed ID: 11325840
[TBL] [Abstract][Full Text] [Related]
4. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
[TBL] [Abstract][Full Text] [Related]
5. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
[TBL] [Abstract][Full Text] [Related]
8. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
9. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
11. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.
Kershaw MH; Jackson JT; Haynes NM; Teng MW; Moeller M; Hayakawa Y; Street SE; Cameron R; Tanner JE; Trapani JA; Smyth MJ; Darcy PK
J Immunol; 2004 Aug; 173(3):2143-50. PubMed ID: 15265951
[TBL] [Abstract][Full Text] [Related]
12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
13. LEAPS Vaccine Incorporating HER-2/neu Epitope Elicits Protection That Prevents and Limits Tumor Growth and Spread of Breast Cancer in a Mouse Model.
Rosenthal KS; Stone S; Koski G; Zimmerman DH
J Immunol Res; 2017; 2017():3613505. PubMed ID: 28459074
[TBL] [Abstract][Full Text] [Related]
14. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.
Orlandi F; Guevara-Patiño JA; Merghoub T; Wolchok JD; Houghton AN; Gregor PD
Vaccine; 2011 May; 29(20):3646-54. PubMed ID: 21435405
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
16. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
17. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
18. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.
Wang X; Wang JP; Maughan MF; Lachman LB
Breast Cancer Res; 2005; 7(1):R145-55. PubMed ID: 15642163
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
[TBL] [Abstract][Full Text] [Related]
20. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.
Smorlesi A; Papalini F; Orlando F; Donnini A; Re F; Provinciali M
Gene Ther; 2005 Sep; 12(17):1324-32. PubMed ID: 15944732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]